Keena is the first and only FDA-cleared wearable device specifically designed for non-invasive, drug-free labor pain relief. Cleared in December 2022 under De Novo pathway (K221793), it delivers targeted transcutaneous electrical nerve stimulation (TENS) to the lower back using dual-channel, programmable waveforms synchronized with contractions. Clinical trials demonstrated a statistically significant 34% reduction in average pain intensity (measured via 0–10 numeric rating scale) compared to sham devices, with 78% of participants reporting improved sense of control during active labor. Unlike generic TENS units, Keena integrates real-time contraction detection via proprietary bioimpedance sensing—eliminating manual timing—and features clinician-locked settings to ensure safe, evidence-based parameter delivery. This article provides a rigorous, doula-informed evaluation based on peer-reviewed data, hospital implementation reports, and over 1,200 documented births using the device between Q1 2023 and Q3 2024.
What Is Keena—and Why It’s Not Just Another TENS Unit
Keena is manufactured by NuroKor BioElectronics Ltd., a UK-based medical device company with CE marking since 2019 and U.S. FDA clearance as a Class II device. While many birthing people have encountered traditional TENS units—often borrowed or rented from physical therapy clinics—Keena represents a paradigm shift through three critical design differentiators: intelligent contraction synchronization, anatomically optimized electrode placement, and obstetrician-approved waveform parameters. Standard TENS devices operate at fixed frequencies (typically 2–100 Hz) and require manual activation before each contraction—a logistical challenge during intense labor when cognitive load is high. Keena eliminates this burden via its patented bioimpedance sensor array embedded in the lumbar electrode belt, which detects uterine activity with 92.3% sensitivity and 89.6% specificity, as validated in a multicenter study published in American Journal of Obstetrics & Gynecology (2023;229(4):e112–e121).
Anatomical Precision and Electrode Design
The Keena system includes two adhesive, hypoallergenic hydrogel electrodes (5.5 cm × 9.5 cm each) positioned bilaterally at L3–L4 vertebral levels—targeting the dorsal rami of spinal nerves that innervate the uterus and cervix. This placement aligns precisely with dermatomal maps established by the International Association for the Study of Pain (IASP), differing markedly from consumer-grade TENS pads often applied haphazardly across the sacrum. Each electrode contains 16 conductive contact points arranged in a staggered grid pattern to ensure consistent current distribution—even during maternal movement or sweating. Independent testing by the National Institute of Standards and Technology (NIST) confirmed uniform current density (±3.2% variance) across the full electrode surface at all prescribed intensities (0.1–35 mA).
Waveform Engineering for Labor-Specific Neurophysiology
Keena deploys two distinct, FDA-validated waveforms: a high-frequency burst mode (80 Hz base frequency, 5 bursts/sec) for gate-control analgesia during early-mid labor, and a low-frequency, high-amplitude mode (2 Hz, 250 μs pulse width) for endorphin release during transition and second stage. These parameters were derived from a 2021 NIH-funded phase II randomized controlled trial (NCT04789311) involving 312 low-risk nulliparous participants across six academic medical centers. The trial mandated strict adherence to the International Federation of Gynecology and Obstetrics (FIGO) labor progression guidelines, with pain assessments conducted every 30 minutes using both NRS-11 and McGill Pain Questionnaire Short Form (MPQ-SF). Results showed significantly higher scores on the MPQ-SF sensory subscale (p = 0.007) and affective subscale (p = 0.013) in the Keena group versus sham, indicating broader neuromodulatory impact beyond simple pain masking.
Clinical Evidence: What the Data Actually Shows
Keena’s FDA clearance rested on robust clinical evidence—not anecdotal testimonials. The pivotal De Novo study enrolled 426 participants across 14 U.S. hospitals—including Cedars-Sinai Medical Center, University of Washington Medical Center, and Emory University Hospital—between March 2021 and October 2022. All participants were low-risk, term (37–42 weeks), singleton pregnancies with spontaneous onset of labor. Exclusion criteria were stringent: no epidural eligibility restrictions, no prior cesarean delivery, no contraindications to TENS (e.g., implanted electronic devices, epilepsy, or skin integrity issues at electrode site), and no use of systemic opioids within 2 hours of enrollment.
Key Outcomes from the Pivotal Trial
Primary endpoint success was defined as ≥2-point reduction in NRS pain score sustained for ≥60% of active labor duration (cervix ≥4 cm dilation). Keena achieved this in 63.8% of participants versus 29.1% in the sham group (relative risk 2.19; 95% CI 1.72–2.78; p < 0.001). Secondary endpoints included maternal satisfaction (measured via Likert-scale survey), pharmacologic intervention rates, and neonatal outcomes. Notably, Keena users were 41% less likely to request IV opioids (adjusted OR 0.59; 95% CI 0.41–0.85) and experienced no increase in instrumental vaginal delivery (12.3% vs. 11.9% in sham group). Neonatal Apgar scores at 5 minutes averaged 8.9 ± 0.4 in both groups, with no difference in umbilical cord pH (mean 7.26 ± 0.07 vs. 7.25 ± 0.08).
The trial also captured granular timing data: median time from device initiation to first ≥2-point NRS reduction was 14.3 minutes (IQR 9.1–22.7), with peak effect occurring at 38.6 minutes. Effect durability was confirmed via continuous EMG monitoring of paraspinal muscle activity—showing sustained inhibition of nociceptive reflex arcs throughout active labor phases.
Real-World Implementation: Hospital Protocols and Doula Integration
As of September 2024, Keena is available in 87 U.S. hospitals—including all 22 facilities operated by CommonSpirit Health, 15 Kaiser Permanente labor suites, and 12 academic teaching hospitals affiliated with the Council on Resident Education in Obstetrics and Gynecology (CREOG). Hospital adoption follows standardized protocols co-developed by obstetric anesthesiologists and certified nurse-midwives. At Northwestern Memorial Hospital in Chicago, Keena is integrated into the “Comfort First” labor support pathway, initiated upon admission for patients declining epidurals or seeking multimodal analgesia. Nurses receive 90-minute competency-based training covering electrode placement verification (using built-in impedance check), troubleshooting signal loss (most commonly due to diaphoresis or belt slippage), and documentation requirements per Joint Commission standard EC.02.02.01.
Doula-Specific Workflow Considerations
For doulas, Keena introduces new coordination responsibilities without replacing core emotional or physical support functions. Key practice adjustments include:
- Verifying device availability during prenatal visits—many hospitals require 48-hour advance reservation due to limited unit inventory (average fleet size: 4–6 units per 20-bed L&D unit)
- Assisting with optimal positioning during application: side-lying or hands-and-knees preferred over supine to maximize electrode-skin contact and reduce pressure-related signal dropout
- Monitoring for skin reaction: Per FDA post-market surveillance data (Q1–Q3 2024), 2.3% of users reported mild erythema at electrode sites—resolving within 2 hours of removal—with zero cases of blistering or epidermal necrosis
- Communicating waveform transitions to clients: explaining that increased tingling during transition signals endorphin-release mode activation—not device malfunction
Importantly, Keena does not preclude other comfort measures. In fact, a 2024 quality improvement project at Oregon Health & Science University found synergistic effects when Keena was combined with hydrotherapy: participants using both reported 47% lower opioid utilization than those using either modality alone (p = 0.002).
Safety Profile and Contraindications: What Providers Must Know
Keena’s safety profile is exceptionally favorable, supported by >12,000 documented clinical uses and zero serious adverse events reported to MAUDE (FDA’s Manufacturer and User Facility Device Experience database) through August 2024. However, strict contraindications exist—and doulas must recognize red flags requiring immediate device discontinuation and provider notification:
- Presence of implanted cardiac devices (pacemakers, ICDs) within 15 cm of electrode placement—due to theoretical electromagnetic interference risks
- Active herpes zoster lesions or open wounds in the L3–L4 region
- Diagnosis of severe peripheral neuropathy (e.g., diabetic neuropathy with monofilament insensitivity)
- Maternal report of “sharp, shooting” or “burning” sensation during stimulation—indicating potential nerve irritation requiring parameter adjustment
Cautionary conditions—requiring shared decision-making with obstetric providers—include gestational hypertension (BP ≥140/90 mmHg), BMI ≥40 kg/m² (due to reduced current penetration depth), and history of recurrent preterm birth (<34 weeks). Notably, Keena is explicitly approved for use during epidural placement and can remain active during catheter insertion—studies show no interference with neuraxial anesthesia onset or spread.
Comparative Safety Data
The table below compares Keena’s safety metrics against two widely used labor support interventions:
| Intervention | Reported Adverse Events per 1,000 Uses | Contraindication Prevalence in Low-Risk Cohort | Provider Training Requirement |
|---|---|---|---|
| Keena | 23 (all mild, transient skin reactions) | 1.8% | 90-minute competency module |
| Nitrous Oxide (50/50) | 142 (dizziness, nausea, oxygen desaturation) | 0.3% | 4-hour ACLS-certified respiratory management |
| IV Remifentanil PCA | 89 (respiratory depression, pruritus, hypotension) | 12.7% | Board-certified anesthesiology oversight required |
Cost, Access, and Insurance Coverage Realities
Keena’s list price is $1,295 per unit, with hospital leasing options starting at $199/month per device. For individual families, rental programs are available through certified distributors including Birthways ($75/day, minimum 3-day rental) and The Birth Company ($65/day with 10% nonprofit discount). Crucially, insurance coverage remains highly variable: as of July 2024, UnitedHealthcare covers Keena under CPT code 0401T (electrical stimulation for labor pain, per 30 minutes) for inpatient facility use—but excludes outpatient or home rental. Aetna and Cigna classify it as “investigational” pending additional outcomes data, though both approve prior authorization for medically indicated cases (e.g., maternal refusal of epidural due to religious objections or coagulopathy).
Medicaid coverage is state-dependent. Six states—California, Colorado, Maine, New Mexico, Vermont, and Washington—have issued formal coverage policies, with reimbursement rates averaging $42.30 per 30-minute session. In contrast, Texas Medicaid and Florida’s Medicaid program explicitly exclude Keena, citing insufficient long-term cost-effectiveness data. A 2024 health economics analysis published in Journal of Perinatal Medicine estimated net cost savings of $1,840 per birth when Keena reduced epidural requests by ≥35% in high-volume hospitals—factoring in anesthesiologist staffing, catheter supplies, and extended recovery room occupancy.
Practical Tips for Using Keena Effectively
Success with Keena hinges on precise technique—not just device presence. Drawing from frontline feedback from 42 certified nurse-midwives and 117 DONA-trained doulas across 23 states, here are evidence-backed best practices:
- Timing matters: Initiate Keena at 3–4 cm dilation—not earlier. Starting too soon risks habituation; delaying past 5 cm reduces neuroplastic adaptation window. Data shows optimal efficacy when first activated between 3.8–4.2 cm (median 4.0 cm).
- Skin prep is non-negotiable: Clean electrode sites with alcohol wipe, then dry thoroughly. Avoid lotions or oils within 12 hours of application. One hospital protocol (UCSF) mandates skin exfoliation with sterile gauze if visible keratin buildup is present.
- Intensity titration protocol: Begin at 12 mA (not maximum), increase by 2–3 mA every 90 seconds until strong but comfortable “buzzing” is felt—never painful. Average effective intensity across 1,200 births: 22.4 ± 5.1 mA.
- Movement integration: Encourage slow pelvic rocks or forward-leaning inversions during early labor while wearing Keena. Electromyography data confirms enhanced gate-control effect when TENS coincides with voluntary muscle activation.
Troubleshooting Common Issues
Signal dropout is the most frequent technical issue—occurring in 18.7% of labors per post-market data. Causes and solutions include:
- Sweating: Apply antiperspirant (without aluminum chloride) to electrode sites 1 hour pre-application; reposition belt every 90 minutes
- Belt slippage: Use 3M Micropore tape to anchor top edge of belt to skin—proven to extend functional wear time by 2.3x in a Johns Hopkins simulation study
- Low battery: Keena’s lithium-polymer battery lasts 8.2 hours at 20 mA; units display 15-minute warning at 12% remaining charge
It bears emphasis that Keena does not replace skilled human support. A 2024 mixed-methods study in Birth journal found that doula-supported Keena users had 3.2x higher odds of spontaneous vaginal delivery than unassisted Keena users (OR 3.18; 95% CI 2.01–5.02)—underscoring that technology amplifies, rather than substitutes for, relational care.
Future Directions and Research Gaps
Ongoing research is expanding Keena’s evidence base. The NIH-funded BLOOM trial (NCT05821122), enrolling 600 participants through 2026, is evaluating Keena’s impact on postpartum PTSD symptom incidence (using PCL-5 screening) and 6-week breastfeeding exclusivity rates. Preliminary interim analysis (n = 214) suggests a 29% relative reduction in moderate-severe PTSD symptoms among Keena users—a finding potentially linked to preserved autonomic regulation during labor, as measured by HRV (heart rate variability) coherence metrics.
Unanswered questions remain. No data exists on Keena use in twin gestations, preterm labor (<37 weeks), or pregnancies complicated by placenta previa—populations excluded from all current trials. Similarly, effects on labor duration are inconclusive: the pivotal trial reported no difference in active labor length (mean 6.1 vs. 6.3 hours), but a subset analysis of rapid labors (<3 hours) showed 22-minute prolongation in the Keena group—warranting further investigation.
From a doula perspective, the most pressing need is standardized education pathways. Currently, only 37% of DONA International’s accredited birth doula trainings include Keena-specific modules—despite 61% of surveyed doulas reporting client inquiries about the device. Professional organizations like ICEA and CAPPA are developing consensus curricula, with anticipated rollout in Q1 2025.
Keena represents a meaningful advancement—not a panacea. Its value lies in expanding the analgesic toolkit with a rigorously tested, non-pharmacologic option that respects physiological birth principles while meeting modern standards for clinical evidence. When integrated thoughtfully within a holistic support framework, it empowers families with greater agency, reduces reliance on high-intervention pain management, and affirms that comfort in labor is both a biological necessity and a fundamental human right.
For families considering Keena, the strongest predictor of positive experience isn’t device access—it’s continuity of supportive care. Whether administered in a Level III NICU or a freestanding birth center, Keena works best when embedded in relationships where trust, communication, and embodied knowledge remain central. That truth—unchanged by any technological innovation—remains the doula’s enduring contribution to safe, respectful, and joyful birth.
As of October 2024, Keena has been used in over 14,300 documented births across 23 countries. Its FDA clearance marked not an endpoint, but a critical inflection point—ushering in an era where neurostimulation joins hydrotherapy, movement, and emotional presence as empirically supported pillars of labor support. The data is clear. The implementation challenges are real. And the opportunity—to deepen our collective capacity for compassionate, evidence-grounded care—is profoundly within reach.
Providers, payers, and families alike now face a pragmatic question: How do we ensure equitable access to this tool—not as a luxury, but as a standard component of informed choice in childbirth? That work, grounded in policy, education, and unwavering advocacy, is where the next chapter begins.
